Dental Practice Valuation Multiples in 2026

The same practice can fetch $1,690,000 or $2,242,500 from the same buyer in the same week, and the difference has nothing to do with the multiple. It comes down to four lines in a recast spreadsheet that most sellers never read closely, and the buyer's analyst writes them for a living while you write them once in your life.

Here's our call, and plenty of owners will hate it: the EBITDA multiple is the least important number in your transition, and the hours you spend trying to argue your way from 6x to 7x would pay you three times better if you spent them defining EBITDA instead. Multiples are published, benchmarked and roughly fixed by your scale. Your earnings definition is negotiable, private and worth hundreds of thousands. You don't sell a multiple. You sell a number someone else gets to define.

2026's Four Rungs, and Which One You're Actually On

The ladder is not a secret. McLerran & Associates' 2026 guide puts single-doctor add-ons under $1M of EBITDA at 5x to 8x, regional add-ons with $1M to $3M of EBITDA at 7x to 9x, emerging platforms at $3M to $5M of EBITDA at 9x to 11x, and platform-grade groups above $5M of EBITDA at 10x to 12x and up. Transitions Elite's advisory data lands in the same neighborhood from the other direction: roughly 5x to 7x for a well-run single location, up to 10x to 14x for platform-scale groups, with the explicit caveat that there is no single market multiple and individual deals land outside the bands regularly.

Read those two ranges together and the structure is obvious. Scale sets the rung. A solo general practice does not negotiate its way onto the platform rung by being well run; it is on the single-location rung because it is a single location. Being excellent moves you from 5x to 7x within your rung. It does not move you to 11x. Anyone telling you otherwise is selling something.

Which means the honest question is not "what multiple can I get." It is "what number gets multiplied."

One Practice, Two Recasts, $552,500 Apart

Take a practice collecting $1,600,000 a year. The owner personally produces $1,000,000 of that; an associate and hygiene cover the remaining $600,000. After every real expense, including everything the owner runs through the business, $560,000 a year lands in the owner's pocket pre-tax. That's a 35% owner's discretionary margin, which is a genuinely good practice.

A buyer does not pay for owner's discretionary earnings. They pay for earnings after someone else does your clinical work. Replace the owner at 30% of their $1,000,000 of production and that's a $300,000 charge against the P&L, leaving $260,000 of EBITDA.

Now the fight nobody prepares for. This owner has four items a competent seller would add back: $40,000 of a spouse's $60,000 payroll for bookkeeping that would cost $20,000 to replace, $18,000 of vehicle expense, $12,000 of travel and continuing education above a normal budget, and $15,000 of one-time legal fees from a lease dispute. Together that's $85,000 of add-backs. Granted, EBITDA is $345,000.

At 6.5x, the midpoint of the single-location rung, those two versions of the same practice price out at $2,242,500 and $1,690,000. The gap is $552,500 on identical collections, identical patients, identical chairs.

Compare that to winning the multiple argument. Push from 6.5x to 7.5x on the unadjusted $260,000 and you get $1,950,000, a gain of $260,000. A full turn of multiple is worth less than half of what the add-back schedule is worth.

And the doctor compensation rate is bigger still. If the buyer recasts the owner's clinical replacement at 35% of production instead of 30%, that's another $50,000 off EBITDA. At 6.5x, that single percentage assumption moves the price $325,000. One cell in a spreadsheet, a third of a million dollars.

Here's the frame that should concentrate your attention. This owner currently takes $560,000 a year. Post-sale, working as an employed dentist at 30% of production, they take $300,000. That's a $260,000 annual income reduction, and the $2,242,500 price covers about 8.6 years of it before taxes. Lose the add-back argument and the same deal covers 6.5 years. Two years of your life, decided by a bookkeeping conversation.

What Most Owners Get Wrong: Reading DSO Press Releases as a Price Quote

The specific mistake: solo and two-doctor general practice owners between five and ten years from exit who read a 12x headline, apply it to their own EBITDA, and build a retirement plan on the answer. We see it most often in owners collecting $900,000 to $1,600,000 who have been to three transition seminars and now believe their practice is a platform asset with a paperwork problem.

It isn't. A practice doing $300,000 of EBITDA is on the bottom rung, full stop, and the 10x to 14x range in the advisory data describes groups with $5M or more of EBITDA, which is roughly sixteen times the earnings of the practice in our example. The second version of the mistake is worse: the owner who concludes they should bolt on two more locations over four years to reach the next rung. That plan requires you to become a multi-site operator, a role you have never done, financed with debt, at an age when your clinical hours are getting shorter. The multiple arithmetic works. The operating risk is the part that isn't in the brochure.

Our view: if you are more than $1M of EBITDA away from the next rung, stop optimizing for the rung and start optimizing for the recast. We wouldn't buy two practices to chase a turn and a half.

The Consolidation Bid Is Real. It Isn't Bidding for You.

None of this means consolidation is hype. The ADA Health Policy Institute found more than one in four dentists within ten years of graduation were affiliated with a DSO in 2024, drawn from an analysis of nearly 200,000 practicing dentists. That is a structural shift in where new dentists go, and it has two consequences for your valuation that pull in opposite directions.

The good one: there is a deep, well-capitalized buyer pool that will keep bidding for assembled groups, which is why the top rungs have held up. The bad one: that same shift is draining the associate pool that solo owners need in order to grow past their own two hands, and it is shaping what young dentists expect to be paid. If a quarter of your potential successors are already employed somewhere with a signing bonus and a comp floor, your clinical replacement cost goes up, and clinical replacement cost is the line that sets your EBITDA.

Worth knowing where the income floor sits. The Bureau of Labor Statistics puts the median annual wage for dentists at $176,110 as of May 2025, with 6% projected employment growth from 2025 to 2035. That figure is the backstop reference in any income-approach valuation, and it is a reminder that the percentage-of-production comp most buyers use in a recast is frequently richer than the market wage for a dentist who isn't producing $1M. If your replacement comp charge comes in well above the market wage for the hours actually worked, that is a negotiable assumption, not a law.

1,036 Practices Are Already Listed Ahead of You

Supply matters, and the asking side of the market is more crowded and smaller-scale than the headline multiples suggest. The Dental Signal Practice Market Index, built from broker listings, currently tracks 1,036 practices listed for sale. Median collections among those listings run $996,000, with the middle half between $660,000 and $1,500,000 (n=849). For general practices specifically, the median is $957,000 (n=729). Median operatory count is 5, middle half 4 to 7 (n=849). Collections per operatory come in at a median of $200,000, middle half $147,250 to $266,563 (n=726).

Two things follow. First, the practices actually changing hands are single-location, roughly $1M-collections businesses, not platform assets, so when a broker quotes you a range, ask which population it describes. Second, that collections-per-operatory distribution is the fastest tell in diligence. A buyer walking into seven operatories running $140,000 each is looking at underused space with a lease attached, and they will price the chairs you aren't filling as a cost, not a growth story. Three dark operatories is not optionality. It is overhead with a light switch.

Three Line Items That Move Price More Than a Full Turn

• Clinical replacement comp. The percentage, and whether it applies to production or collections, swings EBITDA more than anything else on the page. Document the hours and the mix before someone else assumes them.
• Owner-benefit expenses. Every dollar of personal spend run through the business is a dollar you now have to prove was personal. Unprovable add-backs get thrown out, and a thrown-out add-back costs you its full multiple.
• Hygiene and lease economics. A practice where hygiene covers its own cost plus overhead, in a lease that transfers cleanly at a known rate, gets the top of its rung. One where hygiene loses money and the lease expires in fourteen months gets the bottom.

What Would Change Our Mind

Two things we're watching into 2027. If buyers begin standardizing clinical replacement comp at a published rate, the way lenders standardized debt-service coverage, then the recast stops being negotiable and the multiple genuinely becomes the whole game. We'd reverse this piece's advice the week that happens. And if the sub-$1M EBITDA rung starts expanding on its own, rather than the platform tiers pulling away, that would mean buyers are competing for single locations again, which changes what a solo owner should do with the next five years. Right now neither is happening, and the second one has not happened in a long while.

Five Days of Work Before You Call a Broker

Pull your last 24 months of P&Ls this week and tag every line that is personal, one-time, or above market, with a receipt or a contract behind it. Then calculate your own replacement comp honestly: your actual production, your actual days, at 30% and at 35%, and see what each does to your earnings. Get your lease status and your operatory-level production on one page, because both will be asked for and neither improves after you're in a process. Do all of that before anyone quotes you a multiple, so the first number on the table is yours.

If you want a starting read, our valuation calculator will take your collections, overhead and owner production and show you the EBITDA a buyer would likely recast, plus where that lands you on the 2026 multiple ladder. It takes about four minutes and it is the cheapest way to find out whether your retirement math is built on your number or someone else's. Run your own numbers before your next transition conversation, not after.